Anti-Human Interleukin-20 Antibodies

Abstract

Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.

1 . An isolated anti-human IL20 antibody or an antigen-binding fragment thereof that binds to an epitope comprising at least one residue selected from D78-H103 of mature human IL20 (SEQ ID NO:1), optionally excluding D78. 
     
     
         2 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises a residue selected from the group consisting of D78-K96. 
     
     
         3 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises a residue selected from the group consisting of D78-L93. 
     
     
         4 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises a residue selected from the group consisting of R83-F92. 
     
     
         5 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises a residue selected from group consisting of H79-N90. 
     
     
         6 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises three residues selected from the group consisting of D78-H103. 
     
     
         7 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 2 , wherein the epitope three residues selected from the group consisting of D78-K96. 
     
     
         8 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 3 , wherein the epitope comprises three residues selected from the group consisting of D78-L93. 
     
     
         9 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 4 , wherein the epitope comprises three residues selected from the group consisting of R83-F92. 
     
     
         10 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 5 , wherein the epitope comprises three residues selected from the group consisting of H79-N90. 
     
     
         11 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 6 , wherein the epitope comprises five residues selected from the group consisting of D78-H103. 
     
     
         12 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 7 , wherein the epitope comprises five residues selected from the group consisting of D78-K96. 
     
     
         13 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 9 , wherein the epitope comprises five residues selected from the group consisting of R83-F92. 
     
     
         14 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 8 , wherein the epitope comprises five residues selected from the group consisting of D78-L93. 
     
     
         15 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 10 , wherein the epitope comprises five residues selected from the group consisting of H79-N90. 
     
     
         16 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises residues D78-H103. 
     
     
         17 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises residues D78-K96. 
     
     
         18 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises residues D78-L93. 
     
     
         19 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises residues D78-N90. 
     
     
         20 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 1 , wherein the epitope comprises residues H79 and N90. 
     
     
         21 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 20 , wherein the epitope further comprises residue R83. 
     
     
         22 . The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of  claim 21 , further comprising a residue selected from the group consisting of S85, F91, and L92.